Hybrid Group Singing
The overall objective of the planned future clinical trial is to test the investigator's central hypothesis that habitual singing over several weeks, similar to habitual exercise, will lead to sustained and favorable vascular adaptation, thereby lowering cardiovascular disease (CVD) risk. The overall objective of this
| Condition(s) | Coronary Artery Disease, Elderly |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The overall objective of the planned future clinical trial is to test the investigator's central hypothesis that habitual singing over several weeks, similar to habitual exercise, will lead to sustained and favorable vascular adaptation, thereby lowering cardiovascular disease (CVD) risk. The overall objective of this study is to refine and protocolize the singing interventions and test the feasibility of the future trial design. The investigative team has previously studied solo singing. Collective singing, as in a choir or small group, is associated with a positive sense of social inclusion, well-being, and improved mood, including in older adults. |
| Who can participate | Inclusion Criteria: * history of coronary artery disease (defined as having at least 1 of the following: myocardial infarction, coronary stent, PCI, CABG, coronary stenosis at least 50%, or coronary artery calcification score at least 300 Agatston units) Exclusion Criteria: * Parkinson's disease or tremor * upper arm fistula * fingernail onychomycosis * pregnancy * current tobacco use * current illicit drug use * current excessive alcohol use (defined as more than 14 drinks/week for women, more than 28 drinks/week for men) * unstable CAD (active symptoms of chest discomfort) * supplemental oxygen use * more than mild cognitive impairment (as documented in the medical record by patient's treatment teams) * inability to follow study procedures * non-English speaking |
| Ages | 55 Years to 89 Years |
| Sex | All |
| Lead sponsor | Medical College of Wisconsin |
| Locations | Milwaukee, Wisconsin, United States |
| Start date | 2026-04 |
| NCT ID | NCT07355192 |
| Official listing | https://clinicaltrials.gov/study/NCT07355192 |